Nursing homes face federal False Claims Act charges for allegedly overmedicating residents with antipsychotics,...
By
Tim Mullaney
Sep 04, 2014
Two California nursing homes routinely overmedicated residents with antipsychotics and other drugs “for the convenience of management,” according to federal charges announced Wednesday by the...
Antipsychotic use tied to acute kidney injury, increasing pressure on nursing home reduction efforts
By
Tim Mullaney
Aug 20, 2014
Older people who take antipsychotic medications are at a markedly increased risk of acute kidney injury, according to newly published research findings out of Canada. The study further supports ongoing...
Law firm pursues Risperdal link to gynecomastia
Aug 12, 2014
Following research that indicates a possible link between gynecomastia and use of Risperdal, a law firm says it is continuing to offer legal consultations to those who developed the condition.
Glaxo will stop paying doctors for speaking gigs in industry-leading change
By
Tim Mullaney
Dec 18, 2013
Pharmaceutical giant GlaxoSmithKline will stop paying healthcare professionals to speak about its products, and will alter other marketing and compensation practices that are common in the industry but...
A tough retirement nest egg, the whistle-blowing way
By
James M. Berklan
Nov 07, 2013
Two big reactions hit me when news of Johnson & Johnson’s $2.2 billion Risperdal settlement with the government landed this week. First, J&J probably made a lot more than it’s paying out and,...
Johnson & Johnson to pay $2 billion in settlement over antipsychotic drugs in nursing homes
By
Tim Mullaney
Nov 05, 2013
Pharmaceuticals giant Johnson & Johnson and some subsidiaries will pay more than $2.2 billion to settle claims that they inappropriately promoted antipsychotic drugs for use in nursing homes, the U.S....
Reducing the number of residents with dementia who are on antipsychotics starts with reassessment, experts advised at this week’s American College of Health Care Administrators convocation In Orlando....
Nursing home residents being treated successfully with Risperdal should stay on it, researchers recommend
By
McKnight's Staff
Oct 19, 2012
Taking nursing home residents with dementia off of the antipsychotic drug Risperdal might do more harm than good, according to new research.
Risperdal settlement to cost J&J $181 million
Sep 05, 2012
The payouts will go to 36 states, plus the District of Columbia, which brought consumer fraud charges against Janssen for allegedly deceptively marketing the drug Risperdal to providers treating patients...
J&J to pay $181 million for Risperdal settlement
By
McKnight's Staff
Aug 31, 2012
Janssen Pharmaceuticals, a unit of Johnson & Johnson, will pay $181 million to settle charges that it marketed antipsychotic medications for medically unapproved purposes.